olopatadine intranasal/mometasone, intranasal (Rx)

Brand and Other Names:Ryaltris
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

olopatadine/mometasone

intranasal spray

  • (665mcg/25mcg)/spray

Seasonal Allergic Rhinitis

Indicated for symptoms of seasonal allergic rhinitis

2 sprays per nostril BID

Dosage Modifications

Hepatic impairment

  • Not studied; however, increasing concentrations of mometasone have been reported with severity of hepatic impairment

Renal impairment

  • Mometasone: Not studied
  • Olopatadine
    • Mild, moderate, or severe (single dose): No change in peak plasma concentration for single dose
    • Severe (CrCl <30 mL/min/1.73 m2) at steady-state: AUC 2-fold higher and peak plasma concentration ~10-fold higher

Dosage Forms & Strengths

olopatadine/mometasone

intranasal spray

  • (665mcg/25mcg)/spray

Seasonal Allergic Rhinitis

Indicated for symptoms of seasonal allergic rhinitis in adult and pediatric patients aged ≥12 years

<12 years: Safety and efficacy not established

≥12 years: 2 sprays per nostril BID

Dosage Modifications

Hepatic impairment

  • Not studied; however, increasing concentrations of mometasone have been reported with severity of hepatic impairment

Renal impairment

  • Mometasone: Not studied
  • Olopatadine
    • Mild, moderate, or severe (single dose): No change in peak plasma concentration for single dose
    • Severe (CrCl <30 mL/min/1.73 m2) at steady-state: AUC 2-fold higher and peak plasma concentration ~10-fold higher
Next:

Interactions

Interaction Checker

and olopatadine intranasal/mometasone, intranasal

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (1)

            • desmopressin

              mometasone, intranasal increases toxicity of desmopressin by Other (see comment). Contraindicated. Comment: Increases risk of severe hyponatremia.

            Serious - Use Alternative (0)

              Monitor Closely (19)

              • atazanavir

                atazanavir will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • ceritinib

                mometasone, intranasal increases toxicity of ceritinib by Other (see comment). Modify Therapy/Monitor Closely. Comment: May increase risk of hyperglycemia.

              • clarithromycin

                clarithromycin will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • clobazam

                olopatadine intranasal, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              • cobicistat

                cobicistat will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • darunavir

                darunavir will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • elvitegravir/cobicistat/emtricitabine/tenofovir DF

                elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • idelalisib

                idelalisib will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • indinavir

                indinavir will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • itraconazole

                itraconazole will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • ketoconazole

                ketoconazole will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • levoketoconazole

                levoketoconazole will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • lopinavir

                lopinavir will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • mifepristone

                mifepristone will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • nefazodone

                nefazodone will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • nelfinavir

                nelfinavir will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)

                ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • oxymetazoline intranasal

                oxymetazoline intranasal, olopatadine intranasal. Other (see comment). Modify Therapy/Monitor Closely. Comment: Oxymetazoline has been known to slow the rate, but not affect the extent of absorption of concomitantly administered intranasal products. Do not administer other intranasal products with oxymetazoline intranasal.

              • posaconazole

                posaconazole will increase the level or effect of mometasone, intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              Minor (0)

                Previous
                Next:

                Adverse Effects

                1-10%

                Dysgeusia (3%)

                Epistaxis (1%)

                Nasal discomfort (1%)

                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity to any ingredients of nasal spray

                Cautions

                May cause somnolence; avoid operating heavy machinery or engaging in tasks that require mental alertness and coordination; caution patients against engaging in hazardous occupations requiring complete mental alertness and motor coordination (eg, operating machinery, driving a motor vehicle) after administration

                Avoid concurrent use with alcohol or other central nervous system (CNS) depressants; additional reductions in alertness and additional impairment of CNS performance may occur

                Glaucoma and/or cataracts may develop; closely monitor patients with vision changes or history of increased intraocular pressure, glaucoma, and/or cataracts

                Hypersensitivity reactions, including wheezing, have occurred after nasal administration of mometasone; discontinue therapy if such reactions occur

                Nasal corticosteroids may cause reduction in growth velocity when administered to pediatric patients; routinely monitor growth of pediatric patients; safety and efficacy not established in pediatric patients aged <12 years; not indicated for use in this population

                Hypercorticism and adrenal suppression may occur when nasal corticosteroids are misused by taking higher-than-recommended dosages or in patients at risk for such effects

                Local nasal adverse reactions

                • Epistaxis, nasal ulceration, and nasal septal perforation reported
                • Periodically monitor for signs of adverse effects on nasal mucosa
                • Corticosteroids may impair wound healing; avoid use in patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma until resolved
                • Localized Candida infections of the nose and pharynx have occurred from mometasone intranasal; if infection occurs, discontinue therapy, and treat appropriately; examine periodically for evidence of Candida infection if use is over several months or longer

                Immunosuppression and risk of infections

                • Immunosuppressive drugs (eg, corticosteroids) may increase susceptibility to infection
                • Chickenpox and measles may be more serious or even fatal in susceptible children or adults using corticosteroids
                • Risk of developing an infection based on therapy (ie, dose, duration, route), underlying disease, and/or prior corticosteroid use is unknown
                • If exposed to chickenpox, prophylaxis with varicella zoster immune globulin may be indicated; if exposed to measles, prophylaxis with pooled IM immunoglobulin may be indicated; if chickenpox develops, consider treating with antiviral agents
                • Use with caution in active or quiescent tuberculous infections of the respiratory tract, untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections, or ocular herpes simplex

                Drug interaction overview

                • CNS depressants
                  • Avoid coadministration
                  • Alcohol and other CNS depressants may potentiate somnolence and CNS depression
                • Strong CYP3A4 inhibitors
                  • Use with caution
                  • Strong CYP3A4 inhibitors may inhibit metabolism of, and increase mometasone furoate plasma concentration, and potentially increase risk for adverse reactions
                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy

                Data are unavailable on use in pregnant females to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes

                Animal data

                • Olopatadine: Oral administration of olopatadine to pregnant rats and rabbits caused a decrease in number of live fetuses at maternal doses 120x and 1600x the maximum recommended human daily intranasal dose (MRHDID) on a mg/m2 basis, respectively
                • Mometasone: Administration of mometasone to pregnant rats and rabbits caused increased fetal malformations and decreased fetal survival and growth at doses that produced exposures 1-16x the MRHDID on a mcg/m2 or AUC basis

                Lactation

                Data are unavailable on presence of drug in human milk, effects on breastfed children, or on milk production

                Other corticosteroids are excreted in human milk

                Olopatadine has been identified in milk of nursing rats following oral administration; unknown whether topical nasal administration could result in sufficient systemic absorption to produce detectable quantities in human breast milk

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Olopatadine: Antihistamine (H1 antagonist); inhibits release of histamine from mast cells

                Mometasone: Corticosteroid with potent anti-inflammatory properties; elicits effects on various cells, including mast cells and eosinophils; also elicits effects on inflammatory mediators (eg, histamine, eicosanoids, leukotrienes, cytokines)

                Absorption

                Peak plasma time: 1 hr

                Peak plasma concentration

                • Olopatadine: 19.8 ng/mL
                • Mometasone: 9.92 pg/mL

                AUC

                • Olopatadine: 88.77 ng·hr/mL
                • Mometasone: 58.4 pg·hr/mL

                Distribution

                Protein bound

                • Olopatadine: 55% (binds primarily to serum albumin)
                • Mometasone: 98-99%

                Metabolism

                Olopatadine

                • Not extensively metabolized
                • Metabolites: Olopatadine N-oxide and N-desmethyl olopatadine; at least 6 minor metabolites circulate in human plasma

                Mometasone

                • Metabolized by CYP3A4
                • Metabolites: No major metabolites detectable in plasma; 6ß-hydroxy-mometasone furoate (minor metabolite)

                Elimination

                Half-life

                • Olopatadine: 9 hr
                • Mometasone: 18 hr

                Excretion

                • Olopatadine: 70% (urine [86% unchanged]); 17% (feces)
                • Any absorbed drug is excreted as metabolites mostly via the bile, and to a limited extent, into the urine
                Previous
                Next:

                Administration

                Intranasal Preparation

                Priming

                • Shake bottle gently before each use
                • Prime bottle before initial use by releasing 6 sprays
                • Reprime bottle if unused for >14 days by spraying 2 sprays or until fine mist appears

                Intranasal Administration

                Gently blow nose to clear nostrils

                Administer by intranasal route only

                Hold 1 nostril closed with finger and insert spray pump tip into other nostril, pointing it slightly toward outside of nose, away from nasal septum

                Avoid spraying into eyes or mouth

                Do not blow nose for at least 15 minutes after administration

                Storage

                Store upright with dust cap on at room temperature (20-25ºC [68-77ºF]; excursions permitted at 15-30ºC [59-86ºF])

                Do not freeze or refrigerate

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Next:

                Formulary

                FormularyPatient Discounts

                Adding plans allows you to compare formulary status to other drugs in the same class.

                To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                Adding plans allows you to:

                • View the formulary and any restrictions for each plan.
                • Manage and view all your plans together – even plans in different states.
                • Compare formulary status to other drugs in the same class.
                • Access your plan list on any device – mobile or desktop.

                The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                Tier Description
                1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                NC NOT COVERED – Drugs that are not covered by the plan.
                Code Definition
                PA Prior Authorization
                Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                QL Quantity Limits
                Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                ST Step Therapy
                Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                OR Other Restrictions
                Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                Additional Offers
                Email to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Email Forms to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.